DDInter1881 DDInter1763
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Lipoic acid {u} (Compound) binds {v} (Gene) SLC5A6
SLC5A6 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Dolutegravir {u} (Compound) causes {v} (Side Effect) Rash generalised
Rash generalised {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Raltegravir {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Raltegravir {u} (Compound) upregulates {v} (Gene) ICAM3
ICAM3 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Temsirolimus (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid (Compound) binds SLC5A6 (Gene) and SLC5A6 (Gene) is downregulated by Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir (Compound) causes Rash generalised (Side Effect) and Rash generalised (Side Effect) is caused by Temsirolimus (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir (Compound) upregulates ICAM3 (Gene) and ICAM3 (Gene) is downregulated by Temsirolimus (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)